Healthcare Market Disruptions: New Policies and Innovations

The U.S. Federal Trade Commission (FTC) is maintaining a close watch on the pharmaceutical industry as several blockbuster drugs near the end of their patent protection. Dan Guarnera, director of the FTC’s bureau of competition, emphasized at a Pharma USA conference that the agency is committed to shielding consumers from anti-competitive practices that might lead to higher prices.

Meanwhile, the U.S. Food and Drug Administration (FDA) is advocating for a significant shift in drug testing protocols. A newly issued draft guidance encourages pharmaceutical companies to minimize reliance on animal testing, proposing innovative methods like computer simulations to evaluate the safety of experimental drugs.

Additionally, Eli Lilly has reported promising results from a late-stage trial for its next-generation obesity drug, aiming for leadership in the fiercely contested GLP-1 medication market. This comes as more stringent efforts are being initiated for fair pricing of prescription drugs under President Trump’s most-favored-nation policy, hoping to lessen the U.S. expenditure compared to other developed nations.